Functional analysis of tanshinone IIA that blocks the redox function of human apurinic/apyrimidinic endonuclease 1/redox factor-1

Jiangdong Sui, Mengxia Li, Chengyuan Qian, Shufeng Wang, Yi Cheng, Benjamin P C Chen, Dong Wang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a multifunctional protein possessing both DNA repair and redox regulatory activities. It has been shown that blocking redox function leads to genotoxic, antiangiogenic, cytostatic, and proapoptotic effects in cells. Therefore, the selective inhibitors against APE1’s redox function can be served as potential pharmaceutical candidates in cancer therapeutics. In the present study, we identified the biological specificity of the Chinese herbal compound tanshinone IIA (T2A) in blocking the redox function of APE1. Using dual polarization interferometry, the direct interaction between APE1 and T2A was observed with a KD value at subnanomolar level. In addition, we showed that T2A significantly compromised the growth of human cervical cancer and colon cancer cells. Furthermore, the growthinhibitory or proapoptotic effect of T2A was diminished in APE1 knockdown or redox-deficient cells, suggesting that the cytostatic effect of T2A might be specifically through inhibiting the redox function of APE1. Finally, T2A pretreatment enhanced the cytotoxicity of ionizing radiation or other chemotherapeutic agents in human cervical cancer and colon cancer cell lines. The data presented herein suggest T2A as a promising bioactive inhibitor of APE1 redox activity.

Original languageEnglish (US)
Pages (from-to)2147-2160
Number of pages14
JournalDrug Design, Development and Therapy
Volume8
DOIs
StatePublished - Nov 3 2014

Fingerprint

DNA-(Apurinic or Apyrimidinic Site) Lyase
Oxidation-Reduction
Colonic Neoplasms
Cytostatic Agents
Uterine Cervical Neoplasms
Interferometry
tanshinone
Ionizing Radiation
DNA Repair
Cell Line

Keywords

  • APE1
  • Multifunctional protein
  • Redox activity
  • Tanshinone IIA

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Drug Discovery

Cite this

Functional analysis of tanshinone IIA that blocks the redox function of human apurinic/apyrimidinic endonuclease 1/redox factor-1. / Sui, Jiangdong; Li, Mengxia; Qian, Chengyuan; Wang, Shufeng; Cheng, Yi; Chen, Benjamin P C; Wang, Dong.

In: Drug Design, Development and Therapy, Vol. 8, 03.11.2014, p. 2147-2160.

Research output: Contribution to journalArticle

Sui, Jiangdong ; Li, Mengxia ; Qian, Chengyuan ; Wang, Shufeng ; Cheng, Yi ; Chen, Benjamin P C ; Wang, Dong. / Functional analysis of tanshinone IIA that blocks the redox function of human apurinic/apyrimidinic endonuclease 1/redox factor-1. In: Drug Design, Development and Therapy. 2014 ; Vol. 8. pp. 2147-2160.
@article{e22c3ae1c5994a3dbd6021db669205ec,
title = "Functional analysis of tanshinone IIA that blocks the redox function of human apurinic/apyrimidinic endonuclease 1/redox factor-1",
abstract = "Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a multifunctional protein possessing both DNA repair and redox regulatory activities. It has been shown that blocking redox function leads to genotoxic, antiangiogenic, cytostatic, and proapoptotic effects in cells. Therefore, the selective inhibitors against APE1’s redox function can be served as potential pharmaceutical candidates in cancer therapeutics. In the present study, we identified the biological specificity of the Chinese herbal compound tanshinone IIA (T2A) in blocking the redox function of APE1. Using dual polarization interferometry, the direct interaction between APE1 and T2A was observed with a KD value at subnanomolar level. In addition, we showed that T2A significantly compromised the growth of human cervical cancer and colon cancer cells. Furthermore, the growthinhibitory or proapoptotic effect of T2A was diminished in APE1 knockdown or redox-deficient cells, suggesting that the cytostatic effect of T2A might be specifically through inhibiting the redox function of APE1. Finally, T2A pretreatment enhanced the cytotoxicity of ionizing radiation or other chemotherapeutic agents in human cervical cancer and colon cancer cell lines. The data presented herein suggest T2A as a promising bioactive inhibitor of APE1 redox activity.",
keywords = "APE1, Multifunctional protein, Redox activity, Tanshinone IIA",
author = "Jiangdong Sui and Mengxia Li and Chengyuan Qian and Shufeng Wang and Yi Cheng and Chen, {Benjamin P C} and Dong Wang",
year = "2014",
month = "11",
day = "3",
doi = "10.2147/DDDT.S71124",
language = "English (US)",
volume = "8",
pages = "2147--2160",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Functional analysis of tanshinone IIA that blocks the redox function of human apurinic/apyrimidinic endonuclease 1/redox factor-1

AU - Sui, Jiangdong

AU - Li, Mengxia

AU - Qian, Chengyuan

AU - Wang, Shufeng

AU - Cheng, Yi

AU - Chen, Benjamin P C

AU - Wang, Dong

PY - 2014/11/3

Y1 - 2014/11/3

N2 - Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a multifunctional protein possessing both DNA repair and redox regulatory activities. It has been shown that blocking redox function leads to genotoxic, antiangiogenic, cytostatic, and proapoptotic effects in cells. Therefore, the selective inhibitors against APE1’s redox function can be served as potential pharmaceutical candidates in cancer therapeutics. In the present study, we identified the biological specificity of the Chinese herbal compound tanshinone IIA (T2A) in blocking the redox function of APE1. Using dual polarization interferometry, the direct interaction between APE1 and T2A was observed with a KD value at subnanomolar level. In addition, we showed that T2A significantly compromised the growth of human cervical cancer and colon cancer cells. Furthermore, the growthinhibitory or proapoptotic effect of T2A was diminished in APE1 knockdown or redox-deficient cells, suggesting that the cytostatic effect of T2A might be specifically through inhibiting the redox function of APE1. Finally, T2A pretreatment enhanced the cytotoxicity of ionizing radiation or other chemotherapeutic agents in human cervical cancer and colon cancer cell lines. The data presented herein suggest T2A as a promising bioactive inhibitor of APE1 redox activity.

AB - Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a multifunctional protein possessing both DNA repair and redox regulatory activities. It has been shown that blocking redox function leads to genotoxic, antiangiogenic, cytostatic, and proapoptotic effects in cells. Therefore, the selective inhibitors against APE1’s redox function can be served as potential pharmaceutical candidates in cancer therapeutics. In the present study, we identified the biological specificity of the Chinese herbal compound tanshinone IIA (T2A) in blocking the redox function of APE1. Using dual polarization interferometry, the direct interaction between APE1 and T2A was observed with a KD value at subnanomolar level. In addition, we showed that T2A significantly compromised the growth of human cervical cancer and colon cancer cells. Furthermore, the growthinhibitory or proapoptotic effect of T2A was diminished in APE1 knockdown or redox-deficient cells, suggesting that the cytostatic effect of T2A might be specifically through inhibiting the redox function of APE1. Finally, T2A pretreatment enhanced the cytotoxicity of ionizing radiation or other chemotherapeutic agents in human cervical cancer and colon cancer cell lines. The data presented herein suggest T2A as a promising bioactive inhibitor of APE1 redox activity.

KW - APE1

KW - Multifunctional protein

KW - Redox activity

KW - Tanshinone IIA

UR - http://www.scopus.com/inward/record.url?scp=84908544211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908544211&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S71124

DO - 10.2147/DDDT.S71124

M3 - Article

C2 - 25395832

AN - SCOPUS:84908544211

VL - 8

SP - 2147

EP - 2160

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -